Immunovia AB (OSTO:IMMNOV) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


OSTO:IMMNOV Immunovia AB OSTO:IMMNOV
43 GF Score
Price kr0.19
GF Value kr0.07
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Research & Development?

Immunovia AB OSTO:IMMNOV -6.90% 43 Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:IMMNOV with a GF Score™ of 43/100 and a GF Value™ of kr0.07 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Immunovia AB's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Immunovia AB  (OSTO:IMMNOV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Immunovia AB Research & Development Related Terms

Immunovia AB Research & Development Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Research & Development Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Immunovia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:IMMNOV
43GF Score
Immunovia AB OSTO:IMMNOV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Immunovia AB (OSTO:IMMNOV) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Immunovia AB and its competitors.
Is Immunovia AB's Research & Development too high?
Immunovia AB's current Research & Development is kr0.00 Mil. Overall, Immunovia AB has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Research & Development compare to TMO and DHR?
Immunovia AB's Research & Development of kr0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Immunovia AB and its competitors. Immunovia AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Based on GuruFocus' analysis, Immunovia AB (OSTO:IMMNOV) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.07, compared to a current price of kr0.19 — trading 170% above its estimated fair value. The current Research & Development is kr0.00 Mil. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Immunovia AB (OSTO:IMMNOV), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of kr0.19 is trading 170% above its estimated GF Value™ of kr0.07. GuruFocus considers Immunovia AB to be Significantly Overvalued.

Key valuation signals for OSTO:IMMNOV:

  • Research & Development: kr0.00 Mil
  • GF Value™: kr0.07 vs. price of kr0.19 (170% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges 0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for OSTO:IMMNOV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.19
Price
kr0.07
GF Value